, a second generation antipsychotic, that is registered worldwide for the treatment of schizophrenia. Paliperidone is a centrally active dopamine D 2 and serotinergic 5-HT 2A antagonist, as demonstrated in both in vitro and in vivo animal and human studies.
Paliperidone is also active as an antagonist at α 1 -and α 2 -adrenergic receptors and H 1 histaminergic receptors. Paliperidone has no affinity for cholinergic muscarinic or β 1 -and β 2 -adrenergic receptors. (Schotte et al., 1996; Megens and Awouters, 1994; Karlsson et al., 2005) . Paliperidone is a racemate. The pharmacologic profiles of the racemate and the two enantiomers are similar in in vitro binding assays, in vitro receptor occupancy studies, and in in vivo functional interaction studies (unpublished data).
Experiments in humans using positron emission tomography showed that paliperidone occupies central D 2 and 5-HT 2 receptors. The in vivo apparent dissociation constant (K D app )
for central D 2 receptors is estimated to be 4.9 ng/ml (Karlsson et al., 2005) .
Paliperidone extended-release (ER) (3-15 mg once daily [od] ) has been shown to be effective in reducing symptoms of schizophrenia and in improving personal and social performance in short-and long-term studies in the treatment of schizophrenia (Davidson et al., 2007; Kane et al., 2007; Kramer et al., 2007; Marder et al., 2007) .
Paliperidone ER has a slowly ascending plasma concentration-time profile reaching maximum concentrations approximately 24 hours after dosing (Yang and Plosker, 2007) .
In vitro metabolism studies using recombinant human cytochrome P450 enzymes and correlation studies using a panel of human liver microsomes has revealed that both This article has not been copyedited and formatted. The final version may differ from this version. cytochrome P450 (CYP) 2D6 and CYP3A4 are involved in the 9-hydroxylation of risperidone to paliperidone (Fang et al., 1999) . Metabolism experiments of paliperidone with heterologous organisms expressing human CYP3A4 and CYP2D6 suggested the possible involvement of these CYP forms in the metabolism of the drug (unpublished data).
Here we report the absorption, metabolism and excretion of paliperidone in healthy male subjects after a single dose of [ 14 C]paliperidone oral solution. The objective of the study was to characterize the excretion and metabolism of paliperidone and to elucidate the metabolic pathways and the structure of the metabolites. As there are indications that CYP2D6 is involved to some extent in the metabolism of paliperidone, both poor and extensive metabolizers for this isozyme were included in the study.
[Insert Figure 1 near here]
This article has not been copyedited and formatted. The final version may differ from this version. Subjects were healthy based on medical history, a prestudy physical examination, electrocardiogram and clinical laboratory tests. Subjects were non-smokers and had no history of alcohol and drug abuse. Subjects were phenotyped with respect to CYP2D6 using a dextromethorphan metabolic ratio. Two poor (dextromethorphan metabolic ratio >0.345) and three extensive metabolizers (dextromethorphan metabolic ratio <0.0255) participated in the study. Subjects were genotyped with respect to CYP2D6, CYP3A4, CYP3A5, UGT1A1, and UGT1A6. No medication other than the study drug was allowed from 14 days prior to dosing of study drug until the end of the study, with the exception of emergency medication to treat adverse events. Subjects remained in the study center from at least 10 hours before dosing until 168 hours postdose. Subjects fasted from at least 10 hours prior to dosing until 4 hours after. Each subject received a single 1-mg dose of [ 14 C]paliperidone as 10 ml of a 0.1 mg/ml oral solution with a total radioactivity of ∼16 µCi, along with 200 ml of water.
Sample Collections. Blood samples (∼10 ml) were obtained at predose and at 0.5, 1, 1.5, 3, 6, 12, 16, 36, 48, 72, 96, 120, 144 , and 168 hours post dose. In addition, ∼20 ml of blood for the purpose of metabolite profiling and ∼3 ml for the determination of Permafluor (11 ml; Packard) was used as a scintillation cocktail. Duplicate 250-µl aliquots of plasma were diluted with distilled water up to 1 ml, and mixed with 10 ml of Ultima Gold (Packard) as a scintillation cocktail. The total radioactivity levels were expressed as ng-eq./ml using the specific activity of [ 14 C]paliperidone in the drug formulation. The limit of quantification was 72 dpm/mL (2.0 ng-eq/mL)
Urine. Duplicate 0.25-ml aliquots of urine were diluted with distilled water up to 1 ml, and mixed with 10 ml of Ultima Gold (Packard) as a scintillation cocktail.
Feces. Fecal samples were homogenized in methanol with an Ultra-Turrax, centrifuged and residues extracted another two times with methanol, followed by filtration of the suspensions through a Büchner funnel. The methanolic extracts of each fecal sample were combined and duplicate 0.25-ml aliquots were diluted with distilled water up to 1 ml, and mixed with 10 ml of Ultima Gold (Packard) as a scintillation cocktail. The fecal residues were air-dried and the weight of the residues was measured. The dried residues were ground to a fine powder in an Ultra Centrifugal Mill ZM100. Four weighed subsamples of about 100 mg of each residue sample were combusted and measured in a manner similar to that of the blood samples.
Determination of Paliperidone in Plasma.
Paliperidone and risperidone plasma concentrations were determined by an LC-MS/MS assay, based on Method A published by Remmerie et al. (2003) , except for the deviations indicated below. The chromatography A, 20% B and 10% C for 3.1 min, after which a step gradient was applied with 5% A, 10% B and 85% C until 4.1 min; finally, the column was re-equilibrated at 70% A / 20% B / 10% C until 5.5 min. The eluent was split in a ratio of 1:11 in order to introduce 0.1 ml/min into the mass spectrometer. Quantitation was achieved by MS/MS detection in the positive ion mode, using a PE Sciex (Foster City, CA, USA) API 3000 mass spectrometer, equipped with a Turboionspray™ interface. As internal standard, a structural analog, R068808, was used instead of the stable isotope-labeled internal standards to avoid cross-talk from the multiplied by the fraction unbound of paliperidone (fu). CL CR (ml/min) was calculated as CL CR =Ae creat *1000/C CR *1440, where Ae creat is the total cumulative amount of creatinine excreted in urine over 24 hours (µmol) and C CR is the serum creatinine concentration at 12 hours after drug intake (µmol/l). The fu value used (0.23) was determined in a previously published study, in which the protein binding of paliperidone in human plasma from healthy male volunteers was assessed using equilibrium dialysis (Mannens et al., 1994) . Active renal clearance (CL act ) was calculated as the difference between CL R and CL GFR .
Metabolite Profiling in Plasma, Urine and Fecal Extracts. Urine samples of the collection periods between 0 to 12, 12 to 24, 24 to 48, 48 to 96 and 96 to 168 hours, as well as selected methanolic fecal extracts of each subject (representative for the major part of the excreted radioactivity) were pooled by mixing constant fractions of the respective urine and methanolic fecal extract samples.
No radio-HPLC analysis was performed on plasma samples due to the low level of radioactivity (<413 dpm/ml) in the plasma samples. Urine samples of up to 1.9 ml were injected after centrifugation onto the radio-HPLC system. For feces, 10-ml samples of the pooled methanolic extracts were evaporated under nitrogen and the residues were reconstituted in This article has not been copyedited and formatted. The final version may differ from this version. Berthold LB 5035-3 pump at a flow rate of 8.0 ml/min. Detector outputs were connected to the Millennium (Waters) chromatography data system. Elution was started with a linear gradient at a flow rate of 1 ml/min from 100% of an aqueous solution of 0.1 M ammonium acetate adjusted to pH 8.5 (solvent system A) to 50% of solvent system A and 50% of solvent system B composed of an aqueous solution of 1 M ammonium acetate, adjusted to pH 8.5/methanol/acetonitrile (10/10/80, by vol.) over 30 minutes. This solvent composition was held for 5 minutes. Subsequently, a linear gradient over 1 minute to 100% of solvent system B was applied, and this solvent composition was held for another 2 minutes before returning to the starting conditions.
The concentrations of paliperidone and its major metabolites in urine and fecal extracts were calculated based on the recovery of the radioactivity in the samples, as well as on the areas of the radioactivity peaks obtained after reversed-phase radio-HPLC of appropriate aliquots of these samples.
Structural Characterization of Metabolites. Metabolites were identified by LC-MS/MS
and by HPLC co-chromatography of a mixture of the parent compound and synthetic This article has not been copyedited and formatted. The final version may differ from this version. metabolites (see Fig. 1 for structures). The chromatographic part of the apparatus was as outlined above. The LC-MS detector was a Finnigan LCQ (Thermo Electron) or a QTOF Ultima (Waters). For the LCQ mass spectrometer, electrospray ionization was used in the positive mode and the settings were optimized for maximum intensity for paliperidone by using the auto-tune function within the LCQ Tune program. The QTOF mass spectrometer was equipped with a dual electrospray ionization probe and was operated in the positive ion and negative ion mode.
Glucuronic acid and sulfate conjugates excreted in urine were characterized by a comparison of radio-HPLC chromatograms of samples with and without treatment with ß-glucuronidase/arylsulphatase from Helix pomatia (Boehringer, 10 µl per ml of acetate buffered sample, pH 5.0), β-glucuronidase from Escherichia coli (Boehringer, 10 µl per ml of phosphate buffered sample, pH 7.0) and arylsulphatase from Aerobacter aerogenes (Sigma, 10 µl per ml of phosphate buffered sample, pH 7.0). Incubations were performed overnight (16-24 hours) or longer at 37°C. The metabolites in methanolic extracts of human fecal samples were identified by co-chromatography of selected samples with methanolic extracts of fecal samples from an excretion and metabolism study of paliperidone in rats. The chromatographic part of the apparatus was as outlined above.
This article has not been copyedited and formatted. The final version may differ from this version. ). None of the subjects used concomitant medication during the study. Paliperidone was well tolerated, no serious adverse events occurred and no subjects discontinued due to an adverse event. Electrocardiograms, clinical laboratory tests and vital signs showed no clinically relevant changes.
Genotyping and Phenotyping. Subjects were phenotyped for CYP2D6 using dextromethorphan and genotyped for CYP2D6, CYP3A4, CYP3A5, UGT1A1 and UGT1A6.
Based on both phenotyping and genotyping, three subjects were extensive CYP2D6 metabolizers, whereas one subject (105) was a poor CYP2D6 metabolizer. Based on the dextromethorphan metabolic ratio, another subject (103) was phenotyped as being a poor CYP2D6 metabolizer (i.e. having a dextromethorphan metabolic ratio >0.345), but was genotyped to be a heterozygous extensive CYP2D6 metabolizer (CYP2D6 composite genotype: *1/*5). The subject's phenotype value was 0.357, which is close to the antimode (Schmid et al., 1985) . The dextromethorphan metabolic ratio for metabolic characterization of the subjects was used, leading to a total of three extensive CYP2D6 metabolizers and two poor CYP2D6 metabolizers. total radioactivity and unchanged paliperidone were observed around 1.5 hours (median) post dose. The maximum concentration of total radioactivity (mean C max 9.54 ng-eq./ml) was only slightly higher than that of unchanged drug (mean C max 8.85 ng/ml) ( Table 1 ). The terminal half-life of total radioactivity and unchanged drug was on average 15.2 hours and 24.8 hours,
Pharmacokinetics of Radioactivity and
respectively. During the first 24 hours post dose, the percentage of unchanged drug vs. total radioactivity in plasma on average was 97.0%, indicating that the unchanged drug accounted for almost the entire radioactivity in plasma. Renal clearance accounted for about half of the apparent plasma clearance (CL/f) of unchanged drug (on average 53.1 and 91.0 ml/min, respectively). About 50% of the renal clearance of unchanged drug occurred by filtration (average CL GFR : 25.9 ml/min), the other half occurred by active processes (average CL act :
27.2 ml/min) ( Table 2 ).
There were no differences in the overall plasma pharmacokinetics of paliperidone between poor (n=2) and extensive (n=3) CYP2D6 metabolizers as illustrated in Fig. 3 . All subjects belonged to the same CYP3A4 and CYP3A5 genotype, hence this was not further explored.
There was no relationship between the genotypic expression of metabolizing enzymes UGT1A1 and UGT1A6 and the primary pharmacokinetic parameters of exposure (C max , AUC 24 , and AUC ∞ ).
[Insert Figures 2 and 3 and Tables 1 and 2 near here]
Urinary and Fecal Excretion and Mass Balance. The mean and individual cumulative recovery of radioactivity in urine and feces over 0 to 168 hours is depicted in Fig. 4 (Fig. 4) .
[Insert Figure 4 near here]
Blood Distribution of Paliperidone. The distribution of paliperidone between human blood and plasma was determined in samples collected at 2, 4 and 8 h after dosing. The blood-to-plasma ratio ranged on average from 0.78 ± 0.13 to 0.83 ± 0.05, indicating that the radioactivity in blood is mainly distributed to plasma. The level of radioactivity in the 24-hour postdose blood samples was below the limit of detection.
Metabolite Profile of Paliperidone.
No metabolite profiling could be performed in plasma samples, owing to the low level of radioactivity (<413 dpm/ml) in those plasma samples. However, as mentioned previously, unchanged paliperidone accounted for 97% of the total plasma radioactivity over the first 24 hours after dosing. CYP2D6 metabolizers. However, M9 was only detected in the urine of the extensive metabolizers and was not present in the urine samples of the poor metabolizers. The percentages of parent drug recovered in urine samples of the extensive CYP2D6 metabolizers did not differ substantially from those of the poor metabolizers. On the other hand, metabolite M10, which is also a monohydroxylated metabolite at the alicyclic ringsystem, was present in feces of poor metabolizers as well.
The overall recovery of the radioactivity in the methanolic extracts of the stool samples was rather low (mean: 56.8%, range 50-65%). For the stool samples fortified with Metabolite Identification. The structures of the identified metabolites are shown in the metabolic scheme (Fig. 7) . The metabolites were given a numerical code based on the This article has not been copyedited and formatted. The final version may differ from this version. Paliperidone was metabolized to a limited extent; most of the drug was excreted unchanged in the urine. No unchanged drug was detected in the feces. Besides the parent drug, metabolites M1, M9, M12 and M16 could be identified in the urine by LC-MS/MS, and metabolites M10 and M11 were identified in the feces. In addition, an unidentified metabolite was found in the feces of one subject. All metabolites represented small amounts of the total dose administered, with a maximum of 6.48% of the dose (metabolite M1) excreted into urine (Table 2 ) and inappreciable amounts in feces.
The mass fragmentation behavior of radioactive paliperidone (UD) and drug substance (Table 3) .
Identification of M1 in urine by co-chromatography with a mixture of unlabeled authentic compounds was hampered by the interference of endogenous components in urine with the authentic substances, as the low radioactivity levels in the urine necessitated the injection of relatively large quantities of urine. M1 had the same retention time as authentic substance R093725 in overlay plots for urine samples and a separately injected mixture of unlabeled authentic compounds, providing supplementary evidence for the chemical identity of M1.
Moreover, the fragmentation behavior of the authentic compound R093725 and M1 were identical. The exact mass of the protonated molecular ion of R093725 was 239.1032, and that of M1 was 239.1041 (-3.76 ppm) ( Table 3 ). The acid metabolite of paliperidone (M1) formed by mono-hydroxylation of the alicyclic ring and the proposed structure is depicted in Fig. 7 . This was confirmed by exact mass analysis.
M12 had similar mass fragmentation behavior to authentic substance R125239 (Fig. 7 and Table 3 ). The protonated molecular ions m/z 425 in the ESI mass spectra of M12 and the base peak in the MS/MS spectra at m/z 205 were shifted two mass units compared with the parent drug, indicating reduction of the hydroxy group on the hydroxy-methyl-pyrimidine-4-one part of the molecule to a keto function. QT of exact mass analysis confirmed the proposed structure. Metabolite 12, identified in urine, could be formed by alcohol dehydrogenation and also non-enzymatically. For example, it was present in urine samples incubated under conditions for enzymatic hydrolysis with ß-glucuronidase/arylsulphatase in the absence of these hydrolyzing enzymes.
M16, which was identified in urine, had a protonated molecular ion m/z at 606. This was shifted 176 mass units compared with the authentic compound R084852, indicating that M16
could be a glucuronide of R084852 ( Fig. 7 and Table 3 Therefore, M16 could be identified in both studies as a glucuronide of R084852 (M11).
Furthermore, the disappearance of M16 in the chromatograms after enzymatic hydrolysis with ß-glucuronidase/arylsulphatase from Helix pomatia and with ß-glucuronidase from
Escherichia coli was in accordance with the LC-MS/MS findings that M16 is a glucuronide conjugate (Fig. 5 ).
This article has not been copyedited and formatted. The final version may differ from this version. As metabolites in methanolic fecal extracts from rats were present to a significantly larger amount than in human fecal extracts, the metabolites in methanolic extracts of human fecal samples from the present study were identified by co-chromatography of selected samples with methanolic extracts of fecal samples from rats obtained from an in vivo metabolism study in the rat, and LC-MS/MS analysis of the rat feces metabolites that co-eluted with those in human feces. The latter approach was followed because M10 and M11, which were present in the fecal extracts of each subject, could be identified as hydroxylated R084852 (M10) and R084852 (M11) (Fig. 7) . M11 was formed by benzisoxazole scission, whereas M10 was formed by benzisoxazole scission in combination with alicyclic hydroxylation. Another metabolite eluting just behind M10, was detected in a few fecal samples including the pooled fecal extracts of an extensive metabolizer (subject 101) (Fig. 6) , as mentioned before. It was not given a code as it could not be identified.
[Insert Figure 7 and Table 3 near here]
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
The aim of the present study was to characterize the excretion and metabolism of paliperidone in humans and to identify the metabolic pathways and the structures of the metabolites. One week after administration of an oral dose of 1 mg [ 14 C]paliperidone to healthy male subjects, on average 91.1% of the administered radioactivity had been excreted.
The majority of the radioactivity was recovered in the urine (79.6 ± 4.20%), only a small part was excreted into the feces (11.4 ± 3.07%). On average, 59% of the oral dose was excreted unchanged in urine within 7 days, indicating that renal clearance of unchanged drug is the predominant route of elimination for paliperidone. No unchanged drug was detected in fecal extracts. The absolute bioavailability of the instant-release formulation of paliperidone is 106% (Cleton et al., 2006) . These data also suggest that the metabolism of paliperidone is limited.
Renal clearance of paliperidone ranged from 51.4−67.5 ml/min, which is about two-fold higher than the clearance by glomerular filtration, which ranges from 17.0−36.5 ml/min. The clearance by glomerular filtration is calculated by multiplying the creatinine clearance with the fraction unbound of paliperidone, which amounts to 0.23 (Mannens et al., 1994) . This indicates that active tubular secretion probably plays a significant role in the renal clearance of paliperidone. As paliperidone is a cation at physiologic pH, the organic cation transporter may be involved in this active transport. However, data from a human drug−drug interaction study with trimethoprim, an inhibitor of the organic cation transporter, do not indicate clinically relevant changes in renal excretion when co-administered (Cleton et al., 2006a ).
Paliperidone represents the major circulating compound after oral administration of hours, respectively). Due to differences in the lower limit of quantification of the bioanalytical methods, the total radioactivity concentrations were below the limit of quantification of 2.0 ng-eq/mL from 24 hours after dosing onwards, whereas paliperidone could be quantified until 168 hours after dosing (limit of quantification 0.1 ng/mL) (Fig. 2) .
This probably explains the lower half-life and the AUC values extrapolated to infinity of total radioactivity compared to those of unchanged drug.
Paliperidone metabolites were identified using radio HPLC and LC/MS-MS. Interpretation of these data resulted in four metabolites identified in urine ( benzisoxazole scission (formation of R084852, M11), the latter in combination with alicyclic hydroxylation (M10) or glucuronidation (M16; 2.51−5.06%). On average, 7% of the total radioactivity found in urine samples was not identified.
In animal models, paliperidone was mostly metabolized by alicyclic hydroxylation, oxidative N-dealkylation and benzisoxazole scission in rats and dogs, with the additional pathway of alcohol dehydrogenation observed in dogs (unpublished data). Comparison of profiles showed that all metabolites detected in humans were also found in at least one animal species.
This article has not been copyedited and formatted. The final version may differ from this version. In rats, paliperidone and its metabolites were rapidly excreted after p.o. administration;
at 96 hours after dosing, the radioactivity was completely excreted (102.3% of the dose in males, 102.4% of the dose in females) (unpublished data). Excretion occurred predominantly in the feces, comprising ~86% of the dose; ~15% of the dose was excreted in the urine.
Paliperidone was extensively metabolized: unchanged paliperidone accounted for only 3.19%
and 6.42% of the dose in male and female rats, respectively (unpublished data). In dogs, the excretion of TR was somewhat slow; at 168 hours postdose, the major part of the DMD #18275 24 inhibition of CYP2D6 (unpublished data). Although the overall pharmacokinetics were similar between the CYP2D6 poor and extensive metabolizers, the metabolite profile showed minor differences. Metabolite M9, formed by mono-hydroxylation of the alicyclic ring, was only observed in extensive metabolizers, indicating that CYP2D6 is involved in this metabolic pathway. On the other hand, metabolite M10, which is also formed by monohydroxylation of the alicyclic ring was present in feces of a poor metabolizer. Metabolite M12
was detected in one of the two poor CYP2D6 metabolizers. The influence of other metabolizing isozymes on the pharmacokinetics of paliperidone was explored by genotyping subjects for CYP3A4, CYP3A5, UGT1A1 and UGT1A6. As all subjects had the same CYP3A4 and CYP3A5 genotype, this was not explored further. It appeared there is no relationship between the genotypic expression of metabolizing enzymes UGT1A1 and UGT1A6 and paliperidone pharmacokinetics.
In summary, paliperidone was not metabolized extensively in the liver, and renal excretion was the major route of elimination, with 59% of an oral liquid dose excreted unchanged in urine. About half of the renal excretion occurred by active secretion. Other than renal excretion, four metabolic pathways were identified as being involved in the elimination of paliperidone, each of which accounted for up to a maximum of 6.5% of the administered dose.
This article has not been copyedited and formatted. The final version may differ from this version. Total radioactivity concentrations were below the limit of quantification of 2.0 ng-eq/mL from 24 h after dosing onwards; limit of quantification for paliperidone: 0.1 ng/mL. a For total radioactivity, the units for C max and AUC were ng-eq./ml and ng-eq.·h/ml, respectively;
b For the calculation of clearance by glomerular filtration (CL GFR ), the fraction unbound of paliperidone was 0.23. AUC 24h =area under the plasma concentration-time curve from zero to 24 hours; AUC ∞ =area under plasma concentration-time curve from zero to infinity; Ae (% dose) =amount of unchanged drug excreted in the urine/faeces; CL CR =creatinine clearance (ml/min); CL/f=total plasma clearance; CL R =renal clearance; CL GFR =average clearance by glomerular filtration rate; CL ac =active renal clearance; C max= maximum peak plasma concentration; t max= time to maximum peak plasma concentration; t 1/2= terminal half-life This article has not been copyedited and formatted. The final version may differ from this version. 
